Posted 03 December 2015
By Michael Vivion
This article discusses the nuances of FDA Advisory Committee approval meetings and provides an interpretive overview of what regulatory professionals need to know to prepare for a meeting.
Share this article:
Categories: Biologics and biotechnology, Drugs, Medical Devices, Government affairs, Regulatory strategy, Submission and registration, News, US, CBER, CDER, CDRH, Business and Leadership, Communication
Tags: Advisory Committee Meetings, AdComm,